MASH Drug Discovery Strategy: The Power of the 'Multi-Model Portfolio'

MASH Drug Discovery Strategy: The Power of the "Multi-Model Portfolio"

In Search of the Elusive "Super Model"

With the shift from NASH to MASH, the research community continues to search for the Holy Grail: "Is there a mouse model that perfectly reproduces all human pathologies (obesity, insulin resistance, steatosis, inflammation, and fibrosis)?"

However, the conclusion is clear: "No single model perfectly reproduces everything." If you prioritize metabolism, fibrosis tends to be mild. If you accelerate fibrosis, metabolic abnormalities are often compromised. This trade-off is the fate of MASH models.

Today, successful drug discovery projects rarely rely on a single model. Instead, they adopt a "Portfolio Strategy" that combines multiple models with complementary characteristics.

Case Study: The Success of Semaglutide

The accelerated FDA approval of the GLP-1 receptor agonist Semaglutide for MASH was backed by multifaceted preclinical data. Rather than relying on a single model, the development team utilized different models for specific purposes:

1. GAN (Gubra-Amylin NASH) Diet:
   • Models exhibiting obesity, insulin resistance, and moderate fibrosis.
   • Purpose: To evaluate metabolic improvement effects and secondary anti-inflammatory/anti-fibrotic effects.
2. HFD + CCl4:
   • Models with mild metabolic abnormalities but subjected to strong fibrotic triggers.
   • Purpose: To verify direct inhibitory effects on inflammation and fibrosis.
3. STAM™ Model, etc.:
   • Validation in models with a diabetic background.

In essence, they proved "indirect effects via metabolic improvement" and "direct effects on the liver" using separate models, thereby establishing efficacy for the complex human MASH pathology.

Constructing a Strategic Portfolio

It is crucial to build a portfolio tailored to your compound's Mechanism of Action (MoA).

1. Metabolic & Balance Focus (Metabolic Drivers)

• Models: GAN (Gubra-Amylin NASH), STAM™ Model
• Characteristics:
  • GAN: Induced by diets containing saturated fats (palm oil), fructose, and cholesterol (2%), maintaining obesity/insulin resistance with F2-F3 fibrosis (20+ weeks).
  • STAM™: Neonatal Streptozotocin (STZ) injection at postnatal day 2, followed by high-fat diet from 4 weeks of age, rapidly reproducing NASH-to-HCC progression against a diabetic background (~20 weeks).
• Recommended for: GLP-1 agonists, metabolic modifiers, SGLT2 inhibitors.

2. Fibrosis & Inflammation Focus (Fibrotic Drivers)

• Models: CDAHFD (Choline-Deficient/High-Fat), HFD + Low-dose CCl4
• Characteristics:
  • Induces rapid F3-F4 bridging fibrosis (6-12 weeks) via strong inflammation and oxidative stress.
  • May show weight loss or lack of metabolic abnormalities, but offers high sensitivity for the hard endpoint of "fibrosis."
• Recommended for: Anti-fibrotics, anti-inflammatories, TGF-β inhibitors.

Conclusion: CROs as "Partners," Not Just "Catalogs"

Our answer to "Which model is best?" has changed to a counter-question: "Which combination is necessary to prove your drug's strengths?"

MASH drug discovery is a total war. By combining long-term metabolic studies with short-term fibrosis screening, you can significantly increase the Probability of Success (PoS) in clinical trials. Our partner CRO offers this complete lineup of models to support the construction of your "Drug Discovery Portfolio."

---

Related Articles

• Quantitative Assessment of Fibrosis: Sirius Red Staining, Hydroxyproline Assay, and AI Analysis

---

References

1. Rinella ME, et al. Hepatology. 2023. (MASH nomenclature)
2. Tølbøl KS, et al. World J Gastroenterol. 2018. (Liraglutide, OCA, Elafibranor in GAN DIO-NASH model)